13th May 2016 06:35
LONDON (Alliance News) - Hutchison China MediTech Ltd on Friday said it has completed the patient enrolment for its phase 3 trial of its fruquintinib treatment for metastatic colorectal cancer.
The trial will evaluate the efficacy of fruquintinib versus placebo, with the primary endpoint goal overall survival for patients.
"Completing enrollment of our first Phase III clinical trial is an important milestone for our company," said Chief Executive Christian Hogg. "We believe fruquintinib has the potential to significantly improve outcomes in several types of solid tumours."
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed